HTA: Scotland Says Yes To Stelara For Ulcerative Colitis
The decision by the Scottish Medicines Consortium contrasts with recent draft guidance from England’s health technology assessment body, NICE, that recommended against the National Health Service using the Janssen product for ulcerative colitis.
You may also be interested in...
Stelara is a cost-effective use of National Health Service resources, but only where a TNF-alpha inhibitor has failed or cannot be used, and when the product is offered at the price reduction agreed with the health department’s commercial medicines arm, says the latest advice from England’s health technology assessment body, NICE. The move comes after a similar recommendation made earlier this month by NICE’s counterpart in Scotland.
The health technology assessment institute is taking a virtual approach to meetings and has said that it can provide free fast-track advice for companies developing novel diagnostics or therapeutics for the coronavirus.
Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.